Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use MAVENCLAD safely and effectively. See full prescribing information for MAVENCLAD. MAVENCLAD® (cladribine) tablets, for oral use Initial U.S. Approval: 1993
Medication labelWhy this: Advisory · dailymed-prescription
MAVENCLAD is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, use of MAVENCLAD is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS [see Warnings and Precautions (5)]. Limitations of Use MAVENCLAD is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile [see Warnings and Precautions (5)].
- generic_name
- cladribine
- product_names
- Cladribine
- ndc
- 44087-4000, 44087-4000-4, 44087-4000-5, 44087-4000-6, 44087-4000-7, 44087-4000-8, 44087-4000-9, 44087-4000-0
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en